Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition

▸ TREATMENT

A 60-year-old male patient diagnosed in 2019 with BRAF-mutant metastatic CRC and peritoneal metastases experienced an extraordinary response to MEK inhibitor-based treatment. (Frontiers in Oncology)